Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Moodys
McKesson
Baxter
McKinsey

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARIPIPRAZOLE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Aripiprazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00014001 CATIE- Schizophrenia Trial Completed National Institute of Mental Health (NIMH) Phase 4 2000-12-01 The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
NCT00036101 Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2002-02-01 The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.
NCT00036114 Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2000-03-01 The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
NCT00036127 Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 2/Phase 3 2002-04-01 Study to learn if the alternate formulation is effective in agitated schizophrenic patients
NCT00036348 Study of Aripiprazole in Patients With a History of Bipolar Disorder Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2000-03-01 The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with a history of bipolar disorder.
NCT00036361 Broad Effectiveness: Study With Aripiprazole Completed Otsuka America Pharmaceutical Phase 3 2002-07-01 The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aripiprazole

Condition Name

Condition Name for Aripiprazole
Intervention Trials
Schizophrenia 146
Bipolar Disorder 46
Schizoaffective Disorder 24
Major Depressive Disorder 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Aripiprazole
Intervention Trials
Schizophrenia 157
Disease 98
Bipolar Disorder 58
Psychotic Disorders 53
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Aripiprazole

Trials by Country

Trials by Country for Aripiprazole
Location Trials
India 65
Canada 45
Korea, Republic of 36
Mexico 36
Spain 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Aripiprazole
Location Trials
California 97
New York 85
Texas 82
Florida 68
Ohio 67
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Aripiprazole

Clinical Trial Phase

Clinical Trial Phase for Aripiprazole
Clinical Trial Phase Trials
Phase 4 126
Phase 3 105
Phase 2/Phase 3 7
[disabled in preview] 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Aripiprazole
Clinical Trial Phase Trials
Completed 210
Recruiting 40
Terminated 32
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Aripiprazole

Sponsor Name

Sponsor Name for Aripiprazole
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 83
Bristol-Myers Squibb 45
Otsuka America Pharmaceutical 39
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Aripiprazole
Sponsor Trials
Industry 272
Other 265
NIH 29
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
AstraZeneca
Dow
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.